• Shi-Hao He, Yi-Yi Xuan, Xu Liang, Kuang-Jin Guo, Yan Wang, Xiao-Ning Fu, and Tian-Fang Li.
• The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
• Arch Med Sci. 2024 Jan 1; 20 (2): 506516506-516.

AbstractPrimary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease characterized by dryness of the eyes and mouth. The histological feature is mononuclear cell infiltration in exocrine glands, primarily salivary and lachrymal glands. As the disease progresses, some other tissues and organs may be involved and extraglandular manifestations ensue. The major current treatments are palliative and empirical, and in most cases the outcomes are not satisfactory. Emerging data indicate a critical role of lymphocytes in its development and progression. While pioneering work targeting B cells has demonstrated some encouraging results, more trials are warranted to validate the safety and efficacy. In addition, modulation of T cell function with abatacept ameliorates the severity of pSS. Furthermore, clinical trials to inhibit important cytokines involved in its formation have been carried out. In this article, we summarize and compare current biological therapies in order to find new and effective treatments for pSS.Copyright: © 2020 Termedia & Banach.

5 keywords...

hide…